

July 31, 2021

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
--	--

Subject: Outcome of Board Meeting held on Saturday, July 31, 2021

Dear Sir/Madam,

We would like to inform you that, Board Meeting of the Company was held today i.e. Saturday, July 31, 2021 at the registered office of the Company. In pursuant to Regulation 30 and 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board has considered and approved the following matters amongst others:

1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2021. A copy of unaudited financial results along with the Limited Review Report of the Auditors of the Company are enclosed herewith as '**Annexure - I**'.
2. Re-appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as Whole-Time Director of the Company for another period of three years with effect from April 01, 2022 to March 31, 2025. The brief profile is enclosed herewith as '**Annexure - II**'. Further, we would like to state that, as per requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Mrs. Shruti Vishal Rao as Whole-Time Director of the Company have verified and confirmed from her that she is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Mrs. Shruti Vishal Rao being appointed as Whole-Time Director is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.
3. Re-appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as Whole-Time Director of the Company for another period of three year with effect from January 27, 2022 to January 26, 2025. The brief profile is enclosed herewith as '**Annexure - II**'. Further, we would like to state that, as per requirement of Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t Enforcement of SEBI order regarding Appointment of Directors by Listed Companies, the Board of Directors and Nomination and Remuneration Committee while considering the appointment of Dr. Vibha Gagan Sharma as Whole-Time Director of the Company have verified and confirmed from her that she is not debarred from holding the office as a Director pursuant to any SEBI order or any other such authority. Accordingly, we hereby affirm that Dr. Vibha Gagan Sharma being appointed as Whole-Time Director is not debarred from holding the office of Director by virtue of any SEBI order or any other such Authority.



Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

4. Pursuant to Section 188 of the Companies Act, 2013 and based on the recommendation of the Nomination and Remuneration Committee, Audit Committee and subject to approval of the shareholders of the Company, the Board extended the employment contract of Mr. Vishal Vijay Rao for holding office or place of profit as an employee of the Company in the managerial capacity.
5. Re-appointment of M/s. AVS & Associates, Practicing Company Secretaries as Secretarial Auditor of the Company for the financial year 2021-2022. The brief profile of the Secretarial auditor is enclosed herewith as 'Annexure - III'.
6. The Board has constituted the Risk Management Committee pursuant to SEBI (Listing Obligation and Disclosure Requirements) (Second Amendment) Regulations, 2015:
 - Constitution of Risk Management Committee is as follow:

Sr. No.	Name of Members	Designation	Position
1	Mrs. Shilpa Bhatia	Independent Director	Chairman
2	Mr. Gagan Harsh Sharma	Managing Director	Member
3	Mr. Vipul B. Thakkar	Chief Financial Officer	Member

7. The Board has adopted "Dividend Distribution Policy of Bliss GVS Pharma Limited" pursuant to SEBI (Listing Obligation and Disclosure Requirements) (Second Amendment) Regulations, 2015.
8. 36th Annual General Meeting ("AGM") of the Company for the F.Y. 2020-21 has been scheduled to be held on **Tuesday, September 21, 2021** through Video Conferencing ("VC")/ Other Audio Visual Means ("OVAM") facility pursuant to MCA General Circular nos. 14/2020, 17/2020, 20/2020, 02/2021 issued by the Ministry of Corporate Affairs (MCA) and Circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 and SEBI/HO/CFD/CMD2/ CIR/P/2021/11 issued by the SEBI (hereinafter collectively referred to as "the Circulars") which does not require physical presence of members at common venue.

The meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 17:30 p.m.

Kindly take the above information on your record and acknowledge

Thanking you.

Yours Faithfully,

For Bliss GVS Pharma Limited

Vipul B. Thakkar,
Chief Financial Officer



Encl: As above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072

Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021

(₹ in Lakh)

Sr. No	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2021	March 31, 2021	June 30, 2020	March 31, 2021	June 30, 2021	March 31, 2021	June 30, 2020	March 31, 2021
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
I	Revenue from Operations	13,303.05	10,523.24	11,401.88	46,551.31	16,814.54	13,205.34	12,955.00	57,720.54
II	Other Income	789.54	429.88	695.12	1,768.25	781.72	632.67	704.15	2,022.44
III	Total Income (I+II)	14,092.59	10,953.12	12,097.00	48,319.56	17,596.26	13,838.01	13,659.15	59,742.98
IV	Expenses								
a.	Cost of Materials consumed	7,228.50	6,228.92	3,738.06	21,565.36	8,312.65	7,149.45	4,410.56	25,980.84
b.	Purchase of Stock-in-Trade	215.78	470.22	3,129.37	4,649.73	1,384.46	1,323.00	3,650.72	8,097.56
c.	Changes in inventories of work in process, finished goods and stock in trade	(610.10)	(806.39)	69.32	(884.72)	(1,021.11)	(832.36)	(117.59)	(1,187.50)
d.	Employee Benefit Expense	1,538.22	1,599.53	1,409.14	5,860.93	1,773.97	1,898.49	1,603.23	6,809.21
e.	Finance Costs	130.05	201.24	151.99	419.39	139.86	236.24	182.77	551.37
f.	Depreciation and Amortisation Expense	348.13	340.35	342.88	1,376.22	433.41	426.85	428.65	1,722.96
g.	Other Expenses	2,337.58	1,511.75	1,215.55	6,213.98	2,904.43	1,978.19	1,460.36	7,355.84
	Total Expenses	11,188.16	9,545.62	10,056.31	39,200.89	13,927.67	12,179.86	11,618.70	49,330.28
V	Profit / (Loss) before exceptional Items and tax (III-IV)	2,904.43	1,407.50	2,040.69	9,118.67	3,668.59	1,658.15	2,040.45	10,412.70
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	2,904.43	1,407.50	2,040.69	9,118.67	3,668.59	1,658.15	2,040.45	10,412.70
VIII	Tax Expense								
i.	Current Tax	640.07	351.55	394.88	2,152.43	955.29	503.29	436.79	2,604.29
ii.	Deferred Tax Liability/(Asset)	98.56	40.54	(63.80)	116.89	98.79	51.65	(61.40)	123.29
iii.	Short/ Excess Provision of earlier years	-	99.27	-	99.27	1.37	287.96	-	287.96
IX	Net Profit / (Loss) for the period	2,165.80	916.14	1,709.61	6,750.08	2,613.14	815.25	1,665.06	7,397.16
X	Other Comprehensive Income								
i.	Items that will not be reclassified to profit & loss								
(i)	Remeasurement of the defined benefit liabilities/ (asset)	14.94	15.63	(45.99)	70.02	14.94	15.63	(45.99)	70.02
(ii)	Deferred tax on remeasurement of defined benefits liabilities/ (assets)	(3.76)	(3.93)	11.58	(17.62)	(3.76)	(3.93)	11.58	(17.62)
ii.	Items that will be reclassified to profit & loss								
(i)	Exchange differences in translating the financial statements of foreign operations	-	-	-	-	(110.23)	368.93	225.47	(138.56)
(ii)	Deferred tax relating to items that will be reclassified to profit or loss	-	-	-	-	27.74	(67.67)	(159.70)	34.87
XI	Total Comprehensive Income for the period	2,176.98	927.84	1,675.20	6,802.48	2,541.83	1,128.21	1,696.42	7,345.87
XII	Profit/(Loss) attributable to :								
i.	Owners of the Company	-	-	-	-	2,425.42	624.21	1,619.20	6,849.09
ii.	Non-controlling interests	-	-	-	-	187.72	191.04	45.86	548.07
XIII	Other Comprehensive income attributable to :								
i.	Owners of the Company	-	-	-	-	(73.63)	313.67	30.76	(53.07)
ii.	Non-controlling interests	-	-	-	-	2.32	(0.71)	0.60	1.78
XIV	Total Comprehensive income attributable to :								
i.	Owners of the Company	-	-	-	-	2,351.79	937.88	1,649.96	6,796.02
ii.	Non-controlling interests	-	-	-	-	190.04	190.33	46.46	549.85
XV	Paid up equity share capital (Face Value - Re. 1/- each.)	1,033.57	1,031.47	1,031.47	1,031.47	1,033.57	1,031.47	1,031.47	1,031.47
XVI	Earnings Per Share Basic & Diluted (Not Annualised)								
i.	Basic	2.10	0.89	1.66	6.54	2.35	0.61	1.57	6.64
ii.	Diluted	2.04	0.87	1.62	6.40	2.29	0.59	1.54	6.49



Notes :

- 1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules in this regard.
- 2 The current quarter results have been subject to a limited review by the statutory auditors of the company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued report with unmodified opinion on the standalone and consolidated financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 The Group continues to monitor the impact of Covid - 19 on its business, including its impact on customers, supply-chain, employees and logistics. The Group doesn't expect any material impact on this account.
- 5 Employee Benefit Expenses includes Share Based Payment on account of ESOP Scheme, 2019 of ₹ 148.16 Lakhs (Previous Period ₹ 243.01) as per Ind AS 102 for quarter ended June 30, 2021.
- 6 During the quarter ended June 30, 2021, the company has allotted 2,10,500 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the company's ESOP scheme, 2019. From the total number of options granted 34,91,000, the outstanding number of options as at June 30, 2021 are 26,40,500 including 1,44,000 shares for which application money is received pending allotment.
- 7 The figures for the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2021 and the year to date published result for the nine months ended December 31, 2020.

Place : Mumbai
Date : July 31, 2021








For BLISS GVS PHARMA LIMITED

Gagan Harsh Sharma
Managing Director
Din No : 07939421



| Key Highlights for Standalone FY 2021-22 Q1 (June'2021)

FY 2021-22 Q1 (June'2021)		FY 2020-21 Q1 (June'2020)
Revenue from Operation <u>₹ 13,303.05 Lakhs</u>	 16%	Revenue from Operation <u>₹ 11,401.88 Lakhs</u>
EBITDA <u>₹ 2,593.07 Lakhs</u> 19%	 41%	EBITDA <u>₹ 1,840.44 Lakhs</u> 15%
Other Income <u>₹ 789.54 Lakhs</u>	 14%	Other Income <u>₹ 695.12 Lakhs</u>
PBT <u>₹ 2,904.43 Lakhs</u> 21%	 42%	PBT <u>₹ 2,040.69 Lakhs</u> 17%
PAT <u>₹ 2,165.80 Lakhs</u> 15%	 27%	PAT <u>₹ 1,709.61 Lakhs</u> 14%

| Key Highlights for Consolidated FY 2021-22 Q1 (June'2021)

FY 2021-22 Q1 (June'2021)		FY 2020-21 Q1 (June'2020)
Revenue from Operation <u>₹ 16,814.54 Lakhs</u>	↑ 30%	Revenue from Operation <u>₹ 12,955.00 Lakhs</u>
EBITDA <u>₹ 3,460.14 Lakhs</u> 21%	↑ 78%	EBITDA <u>₹ 1,947.72 Lakhs</u> 15%
Other Income <u>₹ 781.72 Lakhs</u>	↑ 11%	Other Income <u>₹ 704.15 Lakhs</u>
PBT <u>₹ 3,668.59 Lakhs</u> 21%	↑ 80%	PBT <u>₹ 2,040.45 Lakhs</u> 15%
PAT <u>₹ 2,613.14 Lakhs</u> 15%	↑ 57%	PAT <u>₹ 1,665.06 Lakhs</u> 12%

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Bliss GVS Pharma Limited,
102, Hyde Park,
Saki Vihar Road,
Andheri (East),
Mumbai 400 072.

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Bliss GVS Pharma Limited** ("the Company"), for the quarter ended June 30, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

5. We draw attention to our reliance on the management representation in respect of the recoverability of the company's investment in, loans given, Interest accrued and Trade receivable to one of its subsidiary and its step-down subsidiary aggregating to Rs. 4,636.97 Lakh.

Our opinion is not modified in respect of this matter.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration No. 104607W/W100166**

D. Sai

**Sai Venkata Ramana Damarla
Partner**

Membership No. 107017

UDIN: 21107017AAAA CC 7950

Place: Mumbai

Dated: July 31, 2021.



KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Bliss GVS Pharma Limited,
102, Hyde Park,
Saki Vihar Road,
Andheri (East),
Mumbai -400 072.

LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Bliss GVS Pharma Limited** (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended June 30, 2021 (“the Statement”), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

A. Incorporated in India:

1. Kremoint Pharma Private Limited, India
- 1.1. Eipii Exports Private Limited, India



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

B. Incorporated outside India:

2. Bliss GVS International Pte. Ltd., Singapore
 - 2.1. Greenlife Bliss Healthcare Limited, Nigeria
 3. Bliss GVS Clinic Healthcare Pte. Ltd., Singapore
 4. Asterisk Lifesciences Limited (UK), United Kingdom
 - 4.1. Asterisk Lifesciences (GH) Limited, Ghana
5. Based on our review and procedures conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial statements of 7 subsidiaries included in the statement, whose financial results reflect the Group's share for the quarter ended June 30, 2021 for the under mentioned items. These financial statements and other financial information have been reviewed by other auditors whose reports have been furnished to us by the management, and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such financial statements is based on the report of such other auditors.

(In Lakh)

Particulars	Quarter Ended June 30, 2021
Total Revenue	3,511.49
Profit After Tax	447.34
Total Comprehensive Income	364.85

Our conclusion on the Statement is not modified in respect of the above matter.

**For KALYANIWALLA AND MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration No. 104607W/W100166**

Sai

**Sai Venkata Ramana Damarla
Partner**

Membership No. 107017

UDIN: 21107017AAAACD2447

Place: Mumbai,

Dated: July 31, 2021.



Annexure - II

Brief Profile of Mrs. Shruti Vishal Rao

Particulars	Details of Appointment
Name of Director	Mrs. Shruti Vishal Rao (DIN: 00731501)
Brief Profile	Mrs. Shruti Vishal Rao, aged 36 years, having total 15 years and more experience with Pharma Industry. She holds a bachelor's degree in Engineering from Mumbai University. She is currently designated as Whole-Time Director of the Company. She is a part of promoter group exclusively working for the company and oversees the day to day commercial and trading activities of the Company in India & abroad.
Date of appointment & Term of appointment	Re-Appointment of Mrs. Shruti Vishal Rao (DIN: 00731501) as a Whole-Time Director of the Company for a period of Three years with effect from April 01, 2022 to March 31, 2025.
Disclosure of relationships between directors	Mrs. Shruti Vishal Rao is related to Promoter & Director of the Company in the following manner: <ol style="list-style-type: none"> 1. Daughter of Mr. S. N. Kamath, Promoter of the Company 2. Sister of Dr. Vibha Gagan Sharma, Whole Time Director of the Company. 3. Sister-in-Law of Mr. Gagan Harsh Sharma, Managing Director of the Company.

Brief Profile of Dr. Vibha Gagan Sharma

Particulars	Details of Appointment
Name of Director	Dr. Vibha Gagan Sharma (DIN: 02307289)
Brief Profile	Dr. Vibha Gagan Sharma, aged 38 years, having total 13 years and more experience with Pharma Industry. She holds a bachelor's degree in Dental Surgery from Rajiv Gandhi University of Health Sciences, Karnataka. She is currently designated as Whole-Time Director of the Company. She is a part of promoter group exclusively working for the company and oversees the research & development activities of the Company.
Date of appointment & Term of appointment	Appointment of Dr. Vibha Gagan Sharma (DIN: 02307289) as a Whole-Time Director of the Company for a period of Three years with effect from January 27, 2022 to January 26, 2025.
Disclosure of relationships between directors	Dr. Vibha Gagan Sharma is related to Promoter & Director of the Company in the following manner: <ol style="list-style-type: none"> 1. Daughter of Mr. S. N. Kamath, Promoter of the Company 2. Wife of Mr. Gagan Harsh Sharma, Managing Director of the Company. 3. Sister of Mrs. Shruti Vishal Rao, Whole Time Director of the Company.

Annexure-III

Brief Profile of Secretarial Auditor

Name of the Firm:	AVS & Associates, Practicing Company Secretaries
Area of Services:	<ul style="list-style-type: none"> • Company Law Matters such as Company and LLP Formation, Conversion of Company into LLP & Vice Versa, Merger & Amalgamation of Companies, Employee Stock Option Plan of Listed Companies, Voluntary Delisting of Shares, Secretarial Audits for Public / Listed Companies, Compounding of Offences & Condonation of Delays with ROC/RD/NCLT etc. • Securities Laws Matters such as Periodical Compliances of Listed Companies (Equity / Debt), Corporate Governance Report, Revocation of Suspension of Trading of Shares, Delisting of Equity Shares, Reclassification of Shareholders of Listed Company. • Foreign Exchange Management Act (FEMA) Matters such as Consultancy relating to FDI / ODI, FCGPR, Annual Return of Foreign Assets & Liabilities, Liaisoning with RBI / AD Banks etc. • Other Matters: Drafting and Vetting of Various Deeds / Agreements / Documents as per Company Law Compliances and any other laws applicable, MSME Registration.
Date of Appointment	31-07-2021
Reason for change:	Re-appointment Secretarial Auditor
Term of Appointment:	F.Y. 2021-2022